Cover Image
Market Research Report
Product code 

Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 115 Pages | Delivery time: 2-3 business days


Back to Top
Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 115 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The global mice model market is expected to register a CAGR of 6.8% over the forecast period, 2021-2026.

Due to the current pandemic situation and the urge to develop treatment and vaccines, mice models have been extensively used in the pre-clinical development by various research laboratories and biopharmaceutical industries. According to an article published by the Science Advisory Board in July 2020, researchers were using a strain of SARS-CoV-2 that can infect mice and further using it to produce a new mouse model of infection to help facilitate testing COVID-19 vaccine candidates and therapies.

There is a significant decline in the application of the mice model in drug development apart from COVID-19, as many countries had been in lockdown and suspended trades, implemented travel restrictions, etc., leading to a decline in market capitalizations of major companies across the world, along with a decline in industrial production and pre-clinical trial, which will negatively impact the market growth.

Factors such as increasing innovations in mice models, rising demand for personalized medicine, and growing pipeline of pharmaceutical and biopharmaceutical companies are driving the growth of the mice model market.

Mice models are one of the best small animal models for various infectious diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Therefore, these mice models are widely used for several different viral investigations in pre-clinical researches.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases (NIAID) reported funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The growing demand to evaluate the effects of drugs on humans, coupled with a rising focus on studying human-specific infections, therapies, and immune responses, promotes the development and use of humanized mice models.

In addition, major companies are focusing on expanding their product portfolios through novel launches. In July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This novel model will save researchers months of planning and accelerate the clinical development of NASH treatment for liver failure.

Thus, the mice model market is expanding, with the increase in R&D activities in pharmaceutical industries. However, alternatives to animal testing and regulations for the ethical use of animals are expected to be the restraints for the growth of the market.

Key Market Trends

The Oncology Segment l is Expected to Hold a Significant Market Share Over the Forecast Period

By application, the oncology segment is expected to hold a significant market share. The major factor propelling the segment's growth is the rising burden of cancer, coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development researches. For instance, in August 2020, researchers in the meeting of the American Chemical Society reported that they were developing a new type of immunotherapy for triple-negative breast cancer. The researchers evaluated this therapy in mice models and concluded that it has dramatically extended the mouse's survival in triple-negative breast cancer.

The Institute of Cancer Research, London, stated that mice could be easily genetically altered to study the genetic causes of cancer and reproduce tumor types that naturally occur in humans. For this, they have been incorporating mice models in their pre-clinical trials for years. In 2017, 2018, and 2019, ICR reported using 26,320, 23,525, and 25,771 mice in pre-clinical oncology testing. These mouse models are expected to revolutionize drug discovery research, such as developing and verifying various cancer therapies, including cancer immunotherapy. Thus, the technological developments and funding by the major players to incorporate mice models in various stages of cancer treatment and diagnostic discoveries will boost the market growth.

North America is Expected to Dominate the Market Over the Forecast Period

Regionally, North America is expected to dominate the mice model market. The concentration of key players in the mice model market is the highest in the North American region. Additionally, the rising number of investments by the government for the development of innovations in mice models is spurring market growth.

For instance, the National Institute on Drug Abuse, the United States, has awarded an assistant professor at The Jackson Laboratory (JAX) an exploratory grant of USD 212,500 to identify genetic pathways involved in addiction behaviors using genome editing in mice models. Under the grant, the researchers will generate five new mice models with variation in Cyfip2 using CRISPR/Cas9 gene-editing technology.

In addition, market players are also focusing on market development strategies in order to increase their market share in the region. In April 2019, LabCorp and Envigo reported that LabCorp's Covance Drug Development segment would acquire Envigo's nonclinical research services business, and Envigo's Research Models Services business will acquire the Covance Research Products business.

Additionally, in November 2019, Envigo announced an agreement to acquire the assets of the business unit of Horizon Discovery Group PLC to combine Horizon transgenic model generation and contract breeding expertise with Envigo's operational and commercial capabilities. This acquisition will boost the US market with new products and services of mice models. All these developments are expected to increase the CAGR of the region during the forecasted period.

Competitive Landscape

The mice model market is made up of a network of players involved in research and product development, component manufacturing, distribution and sales, and post-sale services. The leading players in the market are offering services and CRISPR technologies as service models, which is experiencing an uptrend due to increased drug development activity.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 66012



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Innovation in Mice Models
    • 4.2.2 Rising Demand for Personalized Medicine
    • 4.2.3 Growing Pipeline of Pharmaceutical and Biophamraceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Alternatives to Animal Testing
    • 4.3.2 Regulations for the Ethical Use of Animals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Inbred Mice
    • 5.1.2 Outbred Mice
    • 5.1.3 Genetically Engineered Mice
    • 5.1.4 Hybrid/Congenic Mice
    • 5.1.5 Other Types
  • 5.2 By Service
    • 5.2.1 Breeding
    • 5.2.2 Cryopreservation
    • 5.2.3 Model in-Licensing
    • 5.2.4 Genetic Testing
    • 5.2.5 Other Services
  • 5.3 By Technology
    • 5.3.1 CRISPR/CAS9
    • 5.3.2 Embryonic Stem Cell Injection
    • 5.3.3 Nuclear Transfer
    • 5.3.4 Other Technologies
  • 5.4 By Application
    • 5.4.1 Oncology
    • 5.4.2 Cardiovascular Studies
    • 5.4.3 Neurology
    • 5.4.4 Other Applications
  • 5.5 Geography
    • 5.5.1 North America
      • United States
      • Canada
      • Mexico
    • 5.5.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.5.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.5.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allentown LLC
    • 6.1.2 Charles River Laboratories International Inc.
    • 6.1.3 ENVIGO
    • 6.1.4 Genoway
    • 6.1.5 Harbour Biomed
    • 6.1.6 Horizon Discovery Group PLC (Sage Labs Inc.)
    • 6.1.7 Ingenious Targeting Laboratory
    • 6.1.8 Janvier Labs
    • 6.1.9 Ozgene Pty Ltd
    • 6.1.10 PolyGene
    • 6.1.11 Taconic Biosciences Inc.
    • 6.1.12 The Andersons Inc.
    • 6.1.13 The Jackson Laboratory
    • 6.1.14 Trans Genic Inc.